February 13th 2024
The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.
December 21st 2023
Diet and Exercise Intervention Associated With Better pCR in TNBC or HR+, HER2– BC
September 6th 2023Despite seeming to elicit more pathological complete responses in patients with hormone receptor–positive, HER2-negative triple-negative breast cancer receiving neoadjuvant chemotherapy, diet and exercise did not affect relative dose intensity.
Veliparib/Cisplatin May Improve Survival Vs Placebo in BRCA-Like Metastatic TNBC
January 19th 2023Cisplatin plus veliparib appears to improve progression-free survival among patients with BRCA-like metastatic triple-negative breast cancer, but not in those with non–BRCA-like metastatic breast cancer.
Trilaciclib Prior to Sacituzumab Govitecan-hziy Appeared to Reduce AEs in Advanced TNBC
November 3rd 2022Initial findings from a phase 2 trial showed trilaciclib given before sacituzumab govitecan-hziy lessened the severity of adverse effects in patients with unresectable locally advanced or metastatic triple-negative breast cancer.
Pembrolizumab Granted 4 Approvals in Japan for High-Risk TNBC, RCC, and More
October 2nd 2022Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.
Treatment with Pembrolizumab/Chemo Combo May Be a Standard of Care in mTNBC
December 7th 2021Patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer derived a statistically significant survival benefit following treatment with pembrolizumab and chemotherapy.
Adding Carboplatin to Neoadjuvant Paclitaxel Improved Outcomes in TNBC
September 18th 2021Although the addition of carboplatin to neoadjuvant paclitaxel followed by cyclophosphamide helped to improve outcomes for those with treatment-naïve triple-negative breast cancer, the addition of veliparib did not have an impact on pathologic complete response or event-free survival.
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
July 27th 2021Based on results of the KEYNOTE-522 trial, the FDA approved pembrolizumab, the first immunotherapy for this indication, plus chemotherapy as neoadjuvant treatment for patients with early-stage triple-negative breast cancer.